Sijunzi decoction sarcopenia management is gaining attention as a potential therapeutic strategy for the elderly. Sarcopenia involves the progressive loss of skeletal muscle mass and strength. This condition severely impacts the quality of life in geriatric populations globally. Recently, researchers investigated the efficacy of Sijunzi decoction (SJZD) in treating this age-related muscle decline. The clinical study involved sixty-two elderly patients divided into two groups. While the control group received standard care, the research group also consumed the herbal decoction. Initially, both groups had similar baseline characteristics. However, the outcomes differed significantly after the treatment period.

The results showed substantial improvements in several clinical areas. Specifically, the research group demonstrated higher grip strength and faster walking speeds. Furthermore, patients reported enhanced nutritional status and improved cognitive function scores. In contrast, the control group did not show these extensive gains. Notably, body mass index and prealbumin levels increased in the research group. These findings suggest that SJZD effectively targets the multi-factorial nature of geriatric muscle wasting. Consequently, it may offer a viable supplementary option for patients struggling with physical frailty.

Impact of Sijunzi decoction sarcopenia Treatment on Inflammation

Network pharmacology revealed that the active ingredients in SJZD target 36 specific genes associated with muscle loss. Consequently, these ingredients primarily influence the interleukin-17 and TNF signaling pathways. The study also found significantly reduced serum levels of inflammatory markers. Specifically, levels of Interleukin-6 and C-reactive protein dropped after treatment. Additionally, SJZD lowered levels of myostatin, which is a protein that naturally inhibits muscle growth. By reducing peripheral blood inflammation, the decoction fosters an environment conducive to muscle preservation and repair.

Moreover, the therapy appeared remarkably safe for the elderly participants. Researchers monitored markers for liver and kidney function throughout the study. Specifically, levels of alanine aminotransferase and creatinine remained within healthy ranges. Therefore, SJZD presents a promising integrative approach for managing muscle health in aging adults. Practitioners should consider these results when designing comprehensive care plans. Integrating such herbal interventions could potentially improve overall functional independence in the elderly population.

Frequently Asked Questions

What is Sijunzi decoction?

Sijunzi decoction is a traditional herbal formula often used to strengthen the spleen and improve energy. It contains ingredients like Ginseng and Poria, which are known for their health-promoting properties.

How does this decoction help with muscle strength?

The decoction works by reducing systemic inflammation and lowering myostatin levels. This helps prevent muscle breakdown and supports better muscle quality and physical function.

Is Sijunzi decoction safe for the elderly?

In this clinical study, the decoction was well-tolerated. It did not cause adverse effects on liver or kidney functions among the elderly participants.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Yue Y et al. Sijunzi decoction ameliorates geriatric sarcopenia by improving muscle strength, quality, and functions. Medicine (Baltimore). 2026 Apr 03. doi: 10.1097/MD.0000000000047154. PMID: 41931359.

Zhang Y et al. Impact of Chinese herbal medicine on sarcopenia in enhancing muscle mass, strength, and function: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2024.